1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naive patients with advanced non small-cell lung cancer
    Meeting Abstract

    Antonia, S. J.; Kim, S. W.; Spira, A. I.; Ahn, M. J.; Ou, S. H. I.; Stjepanovic, N.; Fasolo, A.; Jager, D.; Ott, P. A.; Wainberg, Z. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM
    Meeting Abstract

    Armstrong, A. J.; Saad, F.; Shore, N. D.; Fizazi, K.; Phung, D.; Dmuchowski, C.; Hirmand, M.; Forer, D.; Scher, H. I.; De Bono, J. S.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Cardiovascular disease (CVD) risk factors and health behaviors after cisplatin-based chemotherapy (CHEM): A multi-institutional study of testicular cancer survivors (TCS) in the Platinum study
    Meeting Abstract

    Abu Zaid, M. I.; Fung, C.; Williams, A.; Sesso, H. D.; Kerns, S. L.; Ardeshir-Rouhani-Fard, S.; Feldman, D. R.; Hamilton, R. J.; Vaughn, D. J.; Beard, C.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy
    Meeting Abstract

    Abou-Alfa, G. K.; Galle, P. R.; Chao, Y.; Brown, K. T.; Heo, J.; Borad, M. J.; Luca, A.; Pelusio, A.; Agathon, D.; Lusky, M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma
    Meeting Abstract

    Agulnik, M.; Tannir, N. M.; Pressey, J. G.; Gounder, M. M.; Cote, G. M.; Roche, M.; Doleman, S.; Blakemore, S. J.; Clawson, A.; Daigle, S.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience
    Meeting Abstract

    Aisner, D.; Sholl, L. M.; Berry, L. D.; Haura, E. B.; Ramalingam, S. S.; Glisson, B. S.; Socinski, M. A.; Waqar, S. N.; Garon, E. B.; Cetnar, J. P.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Abou-Alfa, G. K.; Qin, S.; Ryoo, B. Y.; Lu, S. N.; Yen, C. J.; Feng, Y. H.; Lim, H. Y.; Izzo, F.; Colombo, M.; Sarker, D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)
    Meeting Abstract

    Abou-Alfa, G. K.; Niedzwieski, D.; Knox, J. J.; Kaubisch, A.; Posey, J.; Tan, B. R.; Kavan, P.; Goel, R.; Lammers, P. E.; Bekaii-Saab, T. S.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC)
    Meeting Abstract

    Abou-Alfa, G. K.; Sangro, B.; Morse, M.; Zhu, A. X.; Kim, R. D.; Cheng, A. L.; Kudo, M.; Kang, Y. K.; Chan, S. L.; Antal, J.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Appendiceal enlargement during immunotherapy treatment for melanoma
    Journal Article

    Bello, D. M.; Callahan, M. K.; Busam, K.; Ariyan, C. E.
    Clinical Skin Cancer (2016)

    Fulltext@MSK | Save